
J. Randolph (Randy) Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Your AI-Trained Oncology Knowledge Connection!

J. Randolph (Randy) Hecht, MD, is a professor of clinical medicine at David Geffen School of Medicine, University of California, Los Angeles (UCLA), and the director of the UCLA Gastrointestinal Oncology Program.